

AMENDMENTS TO THE CLAIMS:

1. (Currently Amended) An isolated antibody that is reactive with an extracellular loop(s) of C5aR other than the N-terminal domain, wherein the antibody reduces or inhibits the binding of C5a to C5aR.
2. (Currently Amended) An isolated antibody according to claim 1, wherein the antibody is reactive with an epitope comprising the second extracellular loop (~~residues 175 to 206~~) of C5aR set forth as the amino acid sequence from residue 175 to 206 of SEQ ID NO: 1.
3. (Currently Amended) An isolated antibody that is reactive with the same epitope of C5aR as a monoclonal antibody as deposited with ECACC under accession number 00110609, wherein the antibody reduces or inhibits the binding of C5a to C5aR.
4. (Currently Amended) An isolated antibody that is reactive with the same epitope of C5aR as a monoclonal antibody as deposited with ECACC under accession number 02090226, wherein the antibody reduces or inhibits the binding of C5a to C5aR.
5. (Currently Amended) An isolated antibody that is reactive with the same epitope of C5aR as a monoclonal antibody as deposited with ECACC under accession number ~~02090227~~ 04090801, wherein the antibody reduces or inhibits the binding of C5a to C5aR.
6. (Currently Amended) An isolated antibody that binds to C5aR, wherein the antibody competitively inhibits the binding of a monoclonal antibody as deposited with ECACC under accession number 00110609 to C5aR.
7. (Currently Amended) An isolated antibody that binds to C5aR, wherein the antibody competitively inhibits the binding of a monoclonal antibody as deposited with ECACC under accession number 02090226 to C5aR.

8. (Currently Amended) An isolated antibody that binds to C5aR, wherein the antibody competitively inhibits the binding of a monoclonal antibody as deposited with ECACC under accession number ~~02090227~~ 04090801 to C5aR.

9. (Currently Amended) An isolated antibody according to claim 1, wherein the comparative binding specificity is determined by antibody-antibody competition assays in the presence of C5aR or a polypeptide comprising an extracellular loop of C5aR.

10. (Currently amended) An isolated antibody comprising ~~substantially the same~~ light and heavy chain sequences comprising at least 80% amino acid sequence identity to the amino acid sequences as shown set forth in SEQ ID NO:19 and SEQ ID NO:21 respectively, wherein the antibody reduces or inhibits the binding of C5a to C5aR.

11.-14. (Canceled)

15. (Currently Amended) An isolated antibody comprising substantially the same light and heavy chain sequences comprising at least 80% amino acid sequence identity to the amino acid sequences as shown set forth in SEQ ID NO:15 and SEQ ID NO:17 respectively, wherein the antibody reduces or inhibits the binding of C5a to C5aR.

16.-19. (Canceled)

20. (Currently Amended) An isolated antibody comprising substantially the same light and heavy chain sequences comprising at least 80% amino acid sequence identity to the amino acid sequences as shown set forth in SEQ ID NO:23 and SEQ ID NO:25 respectively, wherein the antibody reduces or inhibits the binding of C5a to C5aR.

21.-24. (Canceled)

25. (Currently Amended) An isolated antibody according to claim 1, wherein the antibody also inhibits activation of neutrophils by a chemoattractant ligand other than C5a.

26. (Currently Amended) An isolated antibody according to claim 1, wherein the antibody is a monoclonal or recombinant antibody.
27. (Currently Amended) An antibody ~~according to claim 1,~~ that is reactive with an extracellular loop(s) of C5aR other than the N-terminal domain, wherein the antibody reduces or inhibits the binding of C5a to C5aR, and wherein the antibody is a chimeric antibody or a humanized antibody.
28. (Currently Amended) An isolated antibody according to claim 1, wherein the antibody is a class IgG2a or class IgG3 antibody.
29. (Currently Amended) A monoclonal antibody selected from the group consisting of a monoclonal antibody as deposited with ECACC under accession number 00110609, a monoclonal antibody as deposited with ECACC under accession number 02090226, and a monoclonal antibody as deposited with ECACC under accession number ~~02090227~~ 04090801.
30. (Original) A hybridoma as deposited with ECACC under accession number 00110609.
31. (Original) A hybridoma as deposited with ECACC under accession number 02090226.
32. (Currently Amended) A hybridoma as deposited with ECACC under accession number ~~02090227~~ 04090801.
33. (Currently Amended) A conjugate comprising:
an antibody ~~of claim 1,~~ that is reactive with an extracellular loop(s) of C5aR other than the N-terminal domain, wherein the antibody reduces or inhibits the binding of C5a to C5aR; and
a therapeutic agent.
34. (Original) A conjugate according to claim 33, wherein the therapeutic agent is a toxin.

35. (Original) A conjugate according to claim 33, wherein the toxin is a *Pseudomonas* exotoxin or a derivative thereof.

36. (Currently Amended) A conjugate comprising:
an antibody of ~~claim 1~~, that is reactive with an extracellular loop(s) of C5aR other than the N-terminal domain, wherein the antibody reduces or inhibits the binding of C5a to C5aR; and
a detectable label

37. (Original) A conjugate according to claim 36, wherein the label is selected from the group consisting of a radiolabel, a fluorescent label, an enzymatic label and contrast media.

38. (Previously Presented) An isolated nucleic acid molecule, the nucleic acid molecule comprising a sequence encoding an antibody of claim 1.

39. (Currently Amended) A composition comprising [[a]] an isolated antibody according to claim 1 and a pharmaceutically acceptable carrier.

40. (Withdrawn – Currently Amended) A method for inhibiting the interaction of a cell bearing C5aR with a ligand thereof, the method comprising exposing the cell to an isolated antibody of ~~any one of~~ claim 1.

41. (Withdrawn – Currently Amended) A method for inhibiting C5aR activity in a cell, the method comprising exposing the cell to an isolated antibody of ~~any one of~~ claim 1.

42. (Withdrawn – Currently Amended) A method of treating a disorder involving neutrophil migration in a subject, the method comprising administering to the subject an isolated antibody of ~~any one of~~ claim 1.

43. (Withdrawn) A method for diagnosing a disorder involving neutrophil migration in a subject, the method comprising contacting a sample obtained from the subject with a conjugate of claim 36, and detecting immunospecific binding between the conjugate and the sample.

44. (Withdrawn) A method according to claim 43, wherein the method is performed *in vitro* using histological specimens or subfractions of tissue or fluid obtained from the subject.

45. (Withdrawn) A method according to claim 43, wherein the method is performed *in vivo*.

46. (Withdrawn – Currently Amended) A method for diagnosing a disorder involving neutrophil migration in a subject, the method comprising administering to the subject an isolated antibody of ~~any one of~~ claim 1 labeled with an imaging agent under conditions so as to form a complex between the antibody and cells presenting C5aR in the subject, and imaging the complex.

47. (Withdrawn) A method according to any one of claim 42, wherein the disorder is an immunopathological disorder.

48. (Withdrawn) A method for delivering a therapeutic agent to a site of inflammation in a subject, the method comprising administering to the subject a conjugate of claim 33.

49. (Withdrawn – Currently Amended) A method for introducing genetic material into cells presenting C5aR, the method comprising contacting the cells with an isolated antibody of claim 1, wherein the antibody is attached to or associated with genetic material.

50. (Withdrawn) A method according to claim 49, wherein the cells presenting C5aR are selected from the group consisting of granulocytes, leukocytes, such as monocytes, macrophages, basophils and eosinophils, mast cells and lymphocytes including T cells, dendritic cells, and non-myeloid cells such as endothelial cells and smooth muscle cells.

51. (Withdrawn – Currently Amended) A method of treating a disorder involving neutrophil migration in a subject, the method comprising introducing into cells of the subject a polynucleotide encoding an isolated antibody according to claim 1 such that the antibody is expressed *in vivo*.

52. (Currently Amended) An isolated antibody comprising:

a heavy chain comprising heavy chain CDR loop sequences CDR1, CDR2 and CDR3 as shown in SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28, respectively; and
a light chain comprising light chain CDR loop sequences as defined by amino acid residues 24 to 39, 55 to 61 and 94 to 102 of the variable light chain sequence as shown in SEQ ID NO:19, wherein the antibody reduces or inhibits the binding of C5a to C5aR.

53. (Currently Amended) An isolated antibody comprising:

a heavy chain comprising heavy chain CDR loop sequences CDR1, CDR2 and CDR3 as shown in SEQ ID NO:29, SEQ ID NO:30 and SEQ ID NO:31, respectively; and
a light chain comprising light chain CDR loop sequences as defined by amino acid residues 24 to 39, 55 to 61 and 94 to 102 of the variable light chain sequence as shown in SEQ ID NO:15, wherein the antibody reduces or inhibits the binding of C5a to C5aR.

54. (Currently Amended) An isolated antibody comprising:

a heavy chain comprising heavy chain CDR loop sequences CDR1, CDR2 and CDR3 as shown in SEQ ID NO:32, SEQ ID NO:33 and SEQ ID NO:34, respectively; and
a light chain comprising light chain CDR loop sequences as defined by amino acid residues 24 to 39, 55 to 61 and 94 to 102 of the variable light chain sequence as shown in SEQ ID NO:23, wherein the antibody reduces or inhibits the binding of C5a to C5aR.